Compare moats

FY2025 10-K: a content library spanning approximately 100 years of production history — roughly 5,300 live-action film titles, 460 animated film titles plus deep episodic series holdings — feeds every segment (streaming, parks, consumer products, theatrical), and the physical parks portfolio (Walt Disney World, Disneyland, Disneyland Paris, Hong Kong Disneyland 48%, Shanghai Disney Resort 43%, Disney Cruise Line) is not replicable at comparable scale (sec.gov dis-20250927.htm, FY ended 2025-09-27).

source: sec.gov

The 2025 Form 10-K opens with a balance sheet and a licensing perimeter that a new entrant cannot assemble: $4.4 trillion in assets and $362.4 billion in stockholders' equity at December 31, 2025, a principal bank subsidiary (JPMorgan Chase Bank, N.A.) with branches in 48 states and Washington, D.C., 318,512 employees across 66 countries, and consolidated supervision as a bank and financial holding company by the Federal Reserve, layered with the OCC, FDIC, SEC, FINRA, CFTC, U.K. PRA/FCA and the ECB over its principal subsidiaries. Item 1 also notes the Bank Holding Company Act restricts holding companies to banking and closely-related activities, so the charter itself is scarce. Rated wide rather than higher because Item 1's own Competition paragraph calls the environments 'highly competitive' and names e-commerce, digital-asset and financial-technology entrants that 'disintermediate traditional banking products'.

source: sec.gov

The FY2025 10-K supports a real but bounded advantage. The Competition section says the company believes "mRNA as a medicine coupled with our capabilities across mRNA technology, drug discovery, development and manufacturing provide us with a competitive advantage," and the Intellectual Property section backs that with more than 260 issued or allowed U.S. patents or applications, more than 140 granted or allowed outside the U.S., 485 pending applications, and latest-to-expire granted patents on all three approved products projected to 2041 in the U.S. and 2036 in Europe. Item 1A cuts the band down from wide: it opens the competition risk with "The vaccine market, and pharmaceutical market more generally, is intensely competitive," says Moderna "ha[s] been excluded from selling our COVID vaccines in many European markets due to a competitor's contract with the European Commission, which does not lapse until year-end 2026," that in RSV it "entered a market already occupied by two larger competitors," and that rivals "have exploited and may in the future exploit their greater size, infrastructure, resources and experience." The same section reports net losses of $2.8 billion in 2025 and $3.6 billion in 2024 against 2025 total revenue of $1.9 billion.

source: sec.gov

The moat is franchise IP and brands: the FY2025 10-K lists Disney, Pixar, Marvel, Star Wars and National Geographic as the top-level pillars of Disney+, and Mickey and Friends, Star Wars, Spider-Man, Disney Princess, Frozen, Avengers and Toy Story among the major licensed properties; the same IP is monetized across theatrical, streaming, parks and licensing windows (sec.gov dis-20250927.htm).

source: sec.gov

The filing's durable advantage is scale rather than a proprietary technology or a stated network effect: $4.4 trillion of assets and $362.4 billion of equity, 318,512 employees, a 48-state branch footprint and a GSIB capital and liquidity regime administered under the Basel III framework. Item 1A repeatedly frames technology as a required expenditure - 'New technologies have required and could require JPMorganChase to increase expenditures to modify its products' and possible 'significant investments in technology' for quantum-resistant encryption - which is a fixed cost the firm spreads over a base few competitors match. The filing asserts no network effect and no switching-cost lock-in.

source: sec.gov

The filing locates the advantage in a patent and know-how estate, not in customer lock-in or cost. Intellectual Property describes "an expansive, multi-layered IP estate" whose platform claims cover mRNA chemistry, sequence optimization, engineering elements, LNP delivery systems and "innovative processes for the manufacture and analysis of mRNA drug substance and formulated drug product," alongside "substantial proprietary know-how associated with related manufacturing processes" and a trademark portfolio of at least 1,400 registrations. Nothing in the filing claims switching costs or a cost advantage; Item 1A says the opposite, that competitors leverage "larger supply chains and greater purchasing power."

source: sec.gov

Clear leader in its two profit engines — TEA's 2024 Theme Index ranks Disney Experiences the top park operator worldwide with Magic Kingdom #1 for 19 straight years (laughingplace.com, 2025-10-24), and the studio topped the 2025 global box office at $6.58B (Screen Daily, 2026-01-04) — but in total video Disney is second: Nielsen's April 2026 Media Distributor Gauge puts Disney at 10.3% of US TV viewing vs YouTube's 13.4% (MediaPost, 2026-06-25). Co-leader is the honest company-level band.

source: sec.gov

Item 1 claims the firm is 'a leader' in five distinct businesses at once, and 'a leading financial services firm based in the United States' - but it claims to be 'a leader', never the leader, and names no rank or peer comparison anywhere in Item 1 or Item 1A. Scale disclosed in the filing (assets, equity, 318,512 employees, 66 countries, CCB 144,196 / CIB 94,563 / AWM 29,722 headcount) puts it in the front rank; the document itself supports a co-leader reading and not a sole-leader one.

source: sec.gov

The Business section opens with the company's own claim that "Moderna is a pioneer and leader in the field of mRNA medicine." The Competition section frames the commercial reality more narrowly as a contest against a small named set: "We largely compete against Pfizer and BioNTech for sales of our COVID vaccines, whose vaccine is also based on mRNA technology. We also compete against other vaccines, including Sanofi and Novavax's." It does not claim a rank anywhere, and it places Moderna behind in the other approved category: in RSV "we compete against Pfizer and GlaxoSmithKline, who entered the U.S. market prior to us, and our RSV sales have been minimal to date."

source: sec.gov

Q3 FY26 (quarter ended June 2026, reported 2026-08-05): domestic Parks & Experiences operating income rose 27% on 11% revenue growth, and streaming operating margin expanded from 6.6% to 12.9% on 11% subscription revenue growth — margin expansion well ahead of volume in both engines (thedesk.net earnings summary). Counterweight: the FY2025 10-K notes MVPD consolidation may pressure linear carriage terms, so pricing power is concentrated in parks and DTC, not linear.

source: sec.gov

Item 1 states the businesses 'generally compete on the basis of the quality and variety of the Firm's products and services, transaction execution, innovation, reputation and price' - price is one of several axes, not absent. Item 1A is explicit that 'Actions by competitors could put pressure on the pricing for JPMorganChase's products and services or could cause it to lose market share, particularly with respect to investment products and traditional banking products,' and separately that higher rates can cause 'the loss of deposits, including where customers transition to higher-yielding products.' The filing states no margin trend supporting stronger pricing power.

source: sec.gov

Item 1A states that "certain U.S. private vaccine market practices, including regarding discounts, rebates and returns, may cause us to realize significantly lower revenues than list prices," and that "in some instances, our competitors have been able to offer more attractive terms than we can, and they may continue to do so in the future." On the flu candidate it says that in a well-developed market Moderna "may need to offer more favorable terms to gain market share (which we may be unable to do), which may negatively impact our profitability." The Commercial section adds that its markets are "characterized, particularly in the U.S. (our largest market), by a fragmented end customer base, unpredictability in orders and seasonality of deliveries."

source: sec.gov

Content/IP owner at the top of the entertainment value chain: produces and owns franchise IP (Disney, Pixar, Marvel, Star Wars, National Geographic, 80%-owned ESPN), distributes it through owned channels (parks, Disney+, Hulu, ESPN DTC, ABC, theatrical), licenses it downstream to consumer-products makers and retailers, and is a major upstream buyer of sports rights (NFL, NBA, MLB, NHL, college football) — including the pending NFL Transaction exchanging a 10% ESPN stake for NFL Network assets (FY2025 10-K, sec.gov dis-20250927.htm).

An AI adopter and a possible AI casualty, not an AI supplier: the filing books no AI revenue line and mentions no data-center or model exposure, and instead carries a dedicated risk factor on 'the development of advanced technologies such as AI' warning of 'competitive disadvantage if competitors are able to deploy AI more quickly or effectively' and of 'replacement or disintermediation of direct customer relationships if AI agents autonomously manage or intermediate financial decisions' - so its AI exposure as filed is defensive and operational rather than a supply-chain position.

A vertically integrated mRNA developer-manufacturer that sits between upstream licensors and government or retail buyers: it in-licenses the Penn modified-mRNA patents non-exclusively through Cellscript and mRNA RiboTherapeutics at low-single-digit royalties and NIAID's prefusion coronavirus spike and prefusion RSV F patents, manufactures drug substance at the owned Norwood MTC campus and individualized therapy at Marlborough, runs Moderna-built plants in the UK, Canada and Australia against multi-year government purchase commitments, and relies on CMOs for critical raw material production and fill-finish.

• Film studios Leader · Deep source: screendaily.com
• Linear networks & ESPN channels Unknown · Moderate source: sec.gov
• Streaming (Disney+ / Hulu / ESPN DTC) Top 3 · Moderate source: mediapost.com
• Theme parks & experiences Leader · Deep source: laughingplace.com

• Asset & Wealth Management (AWM) Top 3 · Moderate source: sec.gov
• Commercial & Investment Bank (CIB) Leader · Deep source: sec.gov
• Consumer & Community Banking (CCB) Leader · Deep source: sec.gov
• Financial transaction processing Top 3 · Moderate source: sec.gov

• Intismeran autogene (mRNA-4157) Unknown · Moderate source: sec.gov
• Spikevax Top 3 · Moderate source: sec.gov
• mNEXSPIKE Top 3 · Moderate source: sec.gov
• mRESVIA Challenger · Moderate source: sec.gov
• mRNA-1010 seasonal influenza vaccine Unknown · Moderate source: sec.gov

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →

Editorial prior, not backtested.

see exactly how it voted →